BioCentury | Jul 22, 2020
Emerging Company Profile

Jnana goes after metabolism-mediating proteins, gains Roche as partner

...Neurocrine Biosciences Inc. (NASDAQ:NBIX) Number of employees: 40 Funds raised: $50 million Investors: Polaris Partners, Avalon...
BioCentury | Jul 7, 2020
Emerging Company Profile

Tessera: engineering mobile genetic elements for gene insertion

...RNA or AAV delivery and ex vivo delivery such as CAR T cells. Companies including Avalon...
BioCentury | Jun 11, 2020
Deals

Cullinan adds first-in-class asset in hot NK cell checkpoint space

...subsidiary. The anti-MICA mAb was being developed at PDI Therapeutics Inc., a company created by Avalon...
...out of the build-to-buy arrangement, which involved PDI and several other portfolio companies, and left Avalon...
...other investors and deals with biopharmas (see “Avalon Seeks Path Forward for Build-to-Buy Assets” ). Avalon...
BioCentury | Dec 9, 2019
Company News

Sanofi broadens oncology capabilities, adds IL-2 program via $2.5B Synthorx takeout

...“Tusk Takeout” ). According to an April proxy statement, Synthorx’s largest shareholders were RA Capital, Avalon...
BioCentury | Nov 13, 2019
Company News

Merck acquiring Avalon lysosomal disorder play Calporta

...Keen to take advantage of the rising importance of autophagy, Merck has acquired Avalon Ventures-backed Calporta...
...treat lysosomal storage and neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. Calporta Therapeutics Inc. is Avalon’s...
...agreed to terminate three of them (see “After Single Exit, Avalon Seeks Path Forward” ). Avalon’s...
BioCentury | Sep 17, 2019
Company News

Couple charged with stealing secrets to form Chinese, U.S. biotech companies

...co-founded GenExosome Technologies Inc., a Nevada corporation, and retained a 40% stake in the company. Avalon...
...Aug. 14, GenExosome Technologies Inc. “terminated Yu Zhou as Co-Chief Executive Officer,” according to an Avalon...
...In addition, the government is seeking forfeiture of over $1.3 million Zhou has received from Avalon...
BioCentury | Sep 13, 2019
Finance

After single exit, Avalon seeks path forward for build-to-buy assets from GSK deal

...Avalon’s Jay Lichter told BioCentury. Sitari was the first company established under the deal between Avalon...
...Avalon and GSK mutually agreed to terminate three. No longer listed on the website of Avalon’s...
...further funding from Avalon, syndicating with other investors, or forging a deal with a biopharma. Avalon...
BioCentury | Sep 11, 2019
Company News

Sept. 11 Company Quick Takes: Glaxo to buy Sitari; plus Aimmune, Xeris, Puma and United Therapeutics

...La Jolla, Calif.), the first company formed and funded under a 2013 build-to-buy partnership between Avalon...
BioCentury | Jul 24, 2019
Company News

Avalon seeks boost from GE cell therapy manufacturing tech

...of Avalon's cell therapies, including its lead candidate, a next generation CAR T therapy. While Avalon...
...New Jersey, GE's platform will be rolled out first in Avalon's GMP facility in Nanjing. Avalon...
...with targeting CD19, lead program AVA-001 also triggers 4-1BB signaling to increase T cell activation. Avalon...
BioCentury | Nov 16, 2018
Financial News

Synthorx proposes $100M IPO ahead of synthetic IL-2 clinical testing

...round in 2016 and $6 million in a 2014 series A financing led by Avalon. Avalon...
Items per page:
1 - 10 of 236
BioCentury | Jul 22, 2020
Emerging Company Profile

Jnana goes after metabolism-mediating proteins, gains Roche as partner

...Neurocrine Biosciences Inc. (NASDAQ:NBIX) Number of employees: 40 Funds raised: $50 million Investors: Polaris Partners, Avalon...
BioCentury | Jul 7, 2020
Emerging Company Profile

Tessera: engineering mobile genetic elements for gene insertion

...RNA or AAV delivery and ex vivo delivery such as CAR T cells. Companies including Avalon...
BioCentury | Jun 11, 2020
Deals

Cullinan adds first-in-class asset in hot NK cell checkpoint space

...subsidiary. The anti-MICA mAb was being developed at PDI Therapeutics Inc., a company created by Avalon...
...out of the build-to-buy arrangement, which involved PDI and several other portfolio companies, and left Avalon...
...other investors and deals with biopharmas (see “Avalon Seeks Path Forward for Build-to-Buy Assets” ). Avalon...
BioCentury | Dec 9, 2019
Company News

Sanofi broadens oncology capabilities, adds IL-2 program via $2.5B Synthorx takeout

...“Tusk Takeout” ). According to an April proxy statement, Synthorx’s largest shareholders were RA Capital, Avalon...
BioCentury | Nov 13, 2019
Company News

Merck acquiring Avalon lysosomal disorder play Calporta

...Keen to take advantage of the rising importance of autophagy, Merck has acquired Avalon Ventures-backed Calporta...
...treat lysosomal storage and neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. Calporta Therapeutics Inc. is Avalon’s...
...agreed to terminate three of them (see “After Single Exit, Avalon Seeks Path Forward” ). Avalon’s...
BioCentury | Sep 17, 2019
Company News

Couple charged with stealing secrets to form Chinese, U.S. biotech companies

...co-founded GenExosome Technologies Inc., a Nevada corporation, and retained a 40% stake in the company. Avalon...
...Aug. 14, GenExosome Technologies Inc. “terminated Yu Zhou as Co-Chief Executive Officer,” according to an Avalon...
...In addition, the government is seeking forfeiture of over $1.3 million Zhou has received from Avalon...
BioCentury | Sep 13, 2019
Finance

After single exit, Avalon seeks path forward for build-to-buy assets from GSK deal

...Avalon’s Jay Lichter told BioCentury. Sitari was the first company established under the deal between Avalon...
...Avalon and GSK mutually agreed to terminate three. No longer listed on the website of Avalon’s...
...further funding from Avalon, syndicating with other investors, or forging a deal with a biopharma. Avalon...
BioCentury | Sep 11, 2019
Company News

Sept. 11 Company Quick Takes: Glaxo to buy Sitari; plus Aimmune, Xeris, Puma and United Therapeutics

...La Jolla, Calif.), the first company formed and funded under a 2013 build-to-buy partnership between Avalon...
BioCentury | Jul 24, 2019
Company News

Avalon seeks boost from GE cell therapy manufacturing tech

...of Avalon's cell therapies, including its lead candidate, a next generation CAR T therapy. While Avalon...
...New Jersey, GE's platform will be rolled out first in Avalon's GMP facility in Nanjing. Avalon...
...with targeting CD19, lead program AVA-001 also triggers 4-1BB signaling to increase T cell activation. Avalon...
BioCentury | Nov 16, 2018
Financial News

Synthorx proposes $100M IPO ahead of synthetic IL-2 clinical testing

...round in 2016 and $6 million in a 2014 series A financing led by Avalon. Avalon...
Items per page:
1 - 10 of 236